JPH07165571A - Disinfecting composition - Google Patents
Disinfecting compositionInfo
- Publication number
- JPH07165571A JPH07165571A JP24874794A JP24874794A JPH07165571A JP H07165571 A JPH07165571 A JP H07165571A JP 24874794 A JP24874794 A JP 24874794A JP 24874794 A JP24874794 A JP 24874794A JP H07165571 A JPH07165571 A JP H07165571A
- Authority
- JP
- Japan
- Prior art keywords
- disinfecting composition
- fatty acid
- cyclic
- acid ester
- polyhydric alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 230000000249 desinfective effect Effects 0.000 title claims abstract description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229920001296 polysiloxane Polymers 0.000 claims abstract description 34
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 28
- 239000000194 fatty acid Substances 0.000 claims abstract description 28
- 229930195729 fatty acid Natural products 0.000 claims abstract description 28
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 25
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 19
- 239000000080 wetting agent Substances 0.000 claims abstract description 15
- 125000002091 cationic group Chemical group 0.000 claims abstract description 6
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 4
- -1 alcohol fatty acid ester Chemical class 0.000 claims description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 23
- 235000011187 glycerol Nutrition 0.000 claims description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 11
- 230000000844 anti-bacterial effect Effects 0.000 claims description 9
- 238000013329 compounding Methods 0.000 claims description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 239000003899 bactericide agent Substances 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 229940009714 erythritol Drugs 0.000 claims description 3
- 235000019414 erythritol Nutrition 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 229940105990 diglycerin Drugs 0.000 claims description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 2
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 claims 1
- 101150035983 str1 gene Proteins 0.000 claims 1
- 238000001035 drying Methods 0.000 abstract description 15
- 238000007788 roughening Methods 0.000 abstract description 4
- 230000002070 germicidal effect Effects 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 1
- 210000004247 hand Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 11
- 229960000686 benzalkonium chloride Drugs 0.000 description 10
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 10
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 239000000645 desinfectant Substances 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 206010011409 Cross infection Diseases 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-M 5-oxo-L-prolinate Chemical compound [O-]C(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-M 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940071139 pyrrolidone carboxylate Drugs 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- ZSDSQXJSNMTJDA-UHFFFAOYSA-N trifluralin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZSDSQXJSNMTJDA-UHFFFAOYSA-N 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、特に手指の消毒に好適
な手荒れのない医療用の消毒用組成物に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a disinfecting composition for medical use which is suitable for disinfecting fingers and hands, and is free from rough skin.
【0002】[0002]
【従来の技術および発明が解決しようとする課題】病院
での院内感染が新聞紙上を賑わす昨今では、医療従事者
にとって院内感染防止は患者の疾患治療に匹敵するくら
い重要な課題となっている。病院内での院内感染は、医
師や看護婦を介して別の患者に感染していることが報告
されており、一人の患者の治療や介護のあと別の患者の
治療にあたる前に、完全に手指の消毒をしなければなら
ない。そのために最近では消毒用エタノールを主成分に
した速乾性の消毒剤が各種検討され市販されている。速
乾性の消毒剤としては、塩化ベンザルコニウム、グルコ
ン酸クロルヘキシジンなどのエタノール溶液が挙げら
れ、局方消毒エタノールに塩化ベンザルコニウム、グル
コン酸クロルヘキシジンを0.1〜4%の割合で添加し
て調製される。しかし、消毒用エタノールのように、エ
タノールを76.9〜81.4v/v%の高濃度含む溶
液を患者が代わる毎に使用すると、手荒れを起こすこと
になる。そのために、消毒が必要であるにも拘わらず、
頻繁に使用されていない場合が多い。手荒れを起こした
手指は菌の付着が多く、二次感染を引き起こしやすいと
いう悪循環になっている。そこで、エタノールを主成分
とする消毒液に皮膚を保護するエモリエント剤を添加し
て手荒れを防止することが考えられる(特開昭57−1
65305号公報、特開平1−132515号公報、特
公平4−33226号公報、特公平5−63446号公
報等)。しかしながら、エモリエント剤を添加するだけ
では手指がべたついて作業にも支障をきたすうえ、殺菌
を目的に添加されている塩化ベンザルコニウム、グルコ
ン酸クロルヘキシジンなどの殺菌剤の効果を低下させる
ことが報告されている。このように、院内感染の防止の
ため毎日何度も手指の消毒をしなければならない医療従
事者や看護婦が安心して使用できる消毒用組成物であっ
て、十分な殺菌力を有し且つ手荒れやべたつきのない速
乾性の消毒用組成物は得られていないのが現状である。
本発明は、上記の問題点を解決するためになされたもの
で、その目的とするところは、十分な殺菌力を有し、か
つ手荒れやべたつきのない速乾性であり、使用頻度の高
い場合にも手荒れを起こさない消毒用組成物を提供する
ことにある。2. Description of the Related Art Nosocomial infections in hospitals have become popular in newspapers nowadays, so that prevention of nosocomial infections has become an important issue for medical staff, comparable to the treatment of patients' diseases. Nosocomial infections in hospitals have been reported to be transmitted to another patient via a doctor or a nurse, and must be completely treated after treatment or care of one patient and before treatment of another. You must disinfect your hands. Therefore, various kinds of quick-drying disinfectants containing ethanol for disinfection as a main component have been studied and marketed recently. Examples of quick-drying disinfectants include ethanol solutions such as benzalkonium chloride and chlorhexidine gluconate. Benzalkonium chloride and chlorhexidine gluconate are added to the disinfectant ethanol in a proportion of 0.1 to 4%. Is prepared. However, if a solution containing ethanol at a high concentration of 76.9 to 81.4 v / v%, such as disinfecting ethanol, is used every time the patient changes, it causes rough hands. Therefore, despite the need for disinfection,
Often not used frequently. The roughened hands are in a vicious circle where many bacteria are attached to the fingers, which easily causes secondary infection. Therefore, it is conceivable to add an emollient agent that protects the skin to an antiseptic solution containing ethanol as a main component to prevent rough skin (Japanese Patent Laid-Open No. 57-171).
65305, JP-A-1-132515, JP-B-4-33226, JP-B5-63446, etc.). However, it has been reported that adding emollients only causes the fingers to become sticky and hinders work, and that the effects of fungicides such as benzalkonium chloride and chlorhexidine gluconate, which have been added for the purpose of sterilization, are reduced. ing. Thus, it is a disinfecting composition that can be safely used by medical staff and nurses who have to disinfect their fingers many times daily to prevent nosocomial infections, and has sufficient sterilizing power and rough hands. The present situation is that a quick-drying disinfecting composition free of stickiness has not been obtained.
The present invention has been made to solve the above problems, the object is to have a sufficient sterilizing power, and quick-drying without rough hands and stickiness, in the case of frequent use. Another object of the present invention is to provide a disinfecting composition that does not cause rough hands.
【0003】[0003]
【課題を解決するための手段】本発明者らは、塩化ベン
ザルコニウム、塩化ベンゼトニウム、グルコン酸クロル
ヘキシジンなどのカチオン性殺菌剤の殺菌力を低下させ
ないエモリエント剤を検討中に、湿潤剤と所定の極性油
および環状または鎖状シリコーンを組み合わせれば手荒
れやべたつきがなく、使用後さらさらとした感触になる
ことを見い出し、本発明を完成させるに至った。即ち、
本発明の消毒用組成物は、低級アルコールと、カチオン
性殺菌剤と、湿潤剤とを含有する消毒用組成物であっ
て、次式1:Means for Solving the Problems The present inventors have been investigating an emollient agent which does not reduce the bactericidal activity of a cationic bactericide such as benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, etc. It has been found that the combination of polar oil and cyclic or chain silicone does not cause rough hands or stickiness and gives a silky feeling after use, thus completing the present invention. That is,
The disinfecting composition of the present invention is a disinfecting composition containing a lower alcohol, a cationic disinfectant and a wetting agent, and has the following formula:
【0004】[0004]
【化2】[(CH3)2SiO]n または HO−
[(CH3)2SiO]n−HEmbedded image [(CH 3 ) 2 SiO] n or HO-
[(CH 3) 2 SiO] n -H
【0005】(式中、nは2〜6の整数を示す。)で表
される環状または鎖状シリコーンおよび/またはIOB
が0.22〜0.85の多価アルコール脂肪酸エステル
(但し、脂肪酸は直鎖又は分岐鎖のいずれでもよい。)
がさらに配合されてなることを特徴とする。ここでいう
消毒用組成物とは、手指の消毒に限らず、手術時の皮膚
や患者の皮膚消毒をはじめ、医療器具など広く医療や家
庭で使用されうる消毒用組成物をさす。(Wherein n represents an integer of 2 to 6) and a cyclic or chain silicone and / or IOB
Of 0.22 to 0.85 of polyhydric alcohol fatty acid ester (provided that the fatty acid may be linear or branched)
Is further compounded. The disinfecting composition here is not limited to finger disinfection, but refers to a disinfecting composition that can be widely used in medical care and at home, such as skin during surgery and skin of patients, medical instruments and the like.
【0006】本発明の消毒用組成物に配合されるカチオ
ン性殺菌剤としては、C8〜C18の塩化ベンザルコニウ
ム、塩化ベンゼトニウム、グルコン酸クロルヘキシジ
ン、臭化アルキルイソキノリニウム、C8〜C24のアル
キルトリメチルアンモニウムクロリド、下記化学構造式
で示されるN−ココイル−L−アルギニンエチルエステ
ル・DLピロリドンカルボン酸塩(以下、CAEと略記
する。):As the cationic bactericide to be added to the disinfecting composition of the present invention, C 8 to C 18 benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, alkylisoquinolinium bromide, C 8 to C 24 alkyltrimethylammonium chloride, N-cocoyl-L-arginine ethyl ester DL pyrrolidonecarboxylate represented by the following chemical structural formula (hereinafter abbreviated as CAE):
【0007】[0007]
【化3】 [Chemical 3]
【0008】(上式中、RCO−はヤシ油脂肪酸残基を
表す。)等が挙げられ、これらのうちの1種ないしは2
種以上が選択され用いられる。本発明の消毒用組成物に
配合されるカチオン性殺菌剤は、通常の殺菌剤の使用濃
度の範囲であれば問題なく、0.02〜4w/v%、好
ましくは殺菌剤の溶解性から0.05〜0.5w/v%
であれば良い。(In the above formula, RCO-represents a coconut oil fatty acid residue.) And the like, and one or two of these can be mentioned.
More than one species are selected and used. The cationic disinfectant compounded in the disinfecting composition of the present invention has no problem as long as it is within the range of the concentration of the usual disinfectant used, and is 0.02 to 4 w / v%, preferably 0 from the solubility of the disinfectant. .05 to 0.5 w / v%
If it is good.
【0009】本発明の組成物に配合される低級アルコー
ルとしては、エタノールまたはイソプロピルアルコール
が好ましい。配合量は、エタノールでは、その殺菌力か
ら76.9〜81.4v/v%が望ましいが、50〜9
9v/v%のエタノール溶液であれば使用出来る。殺菌
効果の増強のためにイソプロピルアルコールを0.5〜
5v/v%配合することも可能である。The lower alcohol to be added to the composition of the present invention is preferably ethanol or isopropyl alcohol. In ethanol, the blending amount is preferably 76.9 to 81.4 v / v% from the viewpoint of its sterilizing power, but 50 to 9
Any 9 v / v% ethanol solution can be used. Isopropyl alcohol 0.5 ~ to enhance the bactericidal effect
It is also possible to mix 5 v / v%.
【0010】次に、本発明で用いられる湿潤剤は、ポリ
エチレングリコール,グリセリン,ジグリセリン,プロ
ピレングリコール,ブチレングリコール,エリスリトー
ル,ジプロピレングリコール,ソルビトール,マルチト
ール等の多価アルコール、ピロリドンカルボン酸、乳酸
ナトリウム、尿素等が挙げられる。そのうち特に、ポリ
エチレングリコール、グリセリン、プロピレングリコー
ル、ブチレングリコール、エリスリトール、ジプロピレ
ングリコールおよびソルビトールよりなる群から選択さ
れる1種または2種以上が好ましい。また、湿潤剤の配
合量は、0.1〜3.0重量%、好ましくは0.2〜
1.5重量%が適当である。0.1重量%未満では手荒
れ防止には不十分であり、3.0重量%を超えるとべた
つきを防ぐことができない。The wetting agent used in the present invention is a polyhydric alcohol such as polyethylene glycol, glycerin, diglycerin, propylene glycol, butylene glycol, erythritol, dipropylene glycol, sorbitol, maltitol, pyrrolidone carboxylic acid, lactic acid. Examples thereof include sodium and urea. Of these, one or more selected from the group consisting of polyethylene glycol, glycerin, propylene glycol, butylene glycol, erythritol, dipropylene glycol and sorbitol are particularly preferable. The wetting agent content is 0.1 to 3.0% by weight, preferably 0.2 to
1.5% by weight is suitable. If it is less than 0.1% by weight, it is not enough to prevent rough hands, and if it exceeds 3.0% by weight, stickiness cannot be prevented.
【0011】次に、上記式1で表される環状または鎖状
シリコーンおよびIOBが0.22〜0.85の多価ア
ルコール脂肪酸エステルは、いずれも所定量以上の湿潤
剤を配合した時に生じるべたつきをより低減化すると共
に、皮膚からの水分の揮散を防ぐために配合されるもの
で、その中でも環状または鎖状シリコーンおよびIOB
が0.22〜0.85の多価アルコール脂肪酸エステル
を共に用いた時に、特にべたつかずさらっとした感触で
且つ低級アルコールによる手荒れ防止の効果に優れてい
る。Next, the cyclic or chain silicone represented by the above formula 1 and the polyhydric alcohol fatty acid ester having an IOB of 0.22 to 0.85 are all sticky when a wetting agent is added in a predetermined amount or more. It is formulated to further reduce water vaporization and prevent evaporation of water from the skin. Among them, cyclic or chain silicone and IOB
When a polyhydric alcohol fatty acid ester of 0.22 to 0.85 is used together, it is particularly not sticky and has a dry feel, and is excellent in the effect of preventing rough hands due to a lower alcohol.
【0012】本発明の消毒用組成物に配合されるIOB
が0.22〜0.85の多価アルコール脂肪酸エステル
としては、全炭素数が9〜15のプロピレングリコール
脂肪酸エステル,全炭素数が15〜27のグリセリン脂
肪酸ジエステル,全炭素数が21〜39のグリセリン脂
肪酸トリエステル,全炭素数が12〜18のソルビタン
脂肪酸エステル,全炭素数が23〜41のペンタエリス
リトール脂肪酸トリエステル,全炭素数が29〜53の
ペンタエリスリトール脂肪酸テトラエステル等が挙げら
れる。これらは単独または任意の混合物として使用する
ことができる。このうち、全炭素数が21〜39のグリ
セリン脂肪酸トリエステル(トリグリセリド)が好適で
ある。このようなトリグリセリドとしては、例えばパナ
セート875(日本油脂株式会社製),トリスターS−
810(日光ケミカルズ株式会社製)等の中鎖脂肪酸ト
リグリセリド、オリーブ油,大豆油,ゴマ油,サフラワ
ー油,トウモロコシ油等の植物油、RA−G−308
(グリセリルトリ2エチルヘキサノエート)合成油等が
挙げられる。このうち特に好ましいのは、RA−G−3
08である。IOBが0.22〜0.85の多価アルコ
ール脂肪酸エステルの配合量は0.2〜5.0重量%、
好ましくは0.5〜3.0重量%である。配合量が0.
2重量%未満ではべたつきが改善されず、また5.0重
量%を超えると製剤的に安定性が悪くなり、使用性的に
は油っぽく感じるので好ましくない。IOB incorporated into the disinfecting composition of the present invention
Examples of the polyhydric alcohol fatty acid ester having 0.22 to 0.85 include propylene glycol fatty acid ester having 9 to 15 total carbon atoms, glycerin fatty acid diester having 15 to 27 total carbon atoms, and 21 to 39 total carbon atoms. Examples thereof include glycerin fatty acid triester, sorbitan fatty acid ester having 12 to 18 carbon atoms, pentaerythritol fatty acid triester having 23 to 41 carbon atoms, and pentaerythritol fatty acid tetraester having 29 to 53 carbon atoms. These can be used alone or as an arbitrary mixture. Of these, glycerin fatty acid triesters (triglycerides) having a total carbon number of 21 to 39 are preferable. Examples of such triglycerides include Panacet 875 (manufactured by NOF CORPORATION), Tristar S-
Medium chain fatty acid triglycerides such as 810 (manufactured by Nikko Chemicals Co., Ltd.), vegetable oils such as olive oil, soybean oil, sesame oil, safflower oil and corn oil, RA-G-308.
(Glyceryl tri-2-ethylhexanoate) synthetic oil and the like can be mentioned. Of these, particularly preferred is RA-G-3.
It is 08. The amount of the polyhydric alcohol fatty acid ester having an IOB of 0.22 to 0.85 is 0.2 to 5.0% by weight,
It is preferably 0.5 to 3.0% by weight. The compounding amount is
If it is less than 2% by weight, the stickiness is not improved, and if it exceeds 5.0% by weight, the stability of the formulation is deteriorated and it feels oily in terms of usability, which is not preferable.
【0013】本発明の消毒用組成物に配合される環状ま
たは鎖状シリコーンは上記式1で表されるもので、組成
物の乾燥直後のべたつきを少量で効果的に抑えるもので
あり、また極性油と違って揮散するために皮膚上にいつ
までも残らないため、使用性の調整剤として最適のもの
である。その配合量は0.1〜2.0重量%が適当であ
る。配合量が0.1重量%未満では、べたつきが改善さ
れず、また2.0重量%を超えると使用時に、シリコー
ン特有の「ぬめり感」がでたり、製剤の安定性も悪くな
るので好ましくない。環状または鎖状シリコーンは、上
記式1でn=7以上になると、消毒用エタノールとの相
溶性が悪くなって好ましくない、また、n=1以下で
は、グリセリンのべたつきを抑える作用がなくなる。The cyclic or chain silicone compounded in the disinfecting composition of the present invention is represented by the above formula 1, which effectively suppresses the stickiness of the composition immediately after drying with a small amount, and is polar. Unlike oil, it volatilizes and does not remain on the skin forever, so it is the most suitable adjuster for usability. The blending amount is suitably 0.1 to 2.0% by weight. If the blending amount is less than 0.1% by weight, the stickiness is not improved, and if it exceeds 2.0% by weight, the "slickness" peculiar to silicone appears at the time of use and the stability of the preparation is deteriorated, which is not preferable. . If n = 7 or more in the above formula 1, the cyclic or chain silicone is unfavorable because the compatibility with ethanol for disinfection becomes poor, and if n = 1 or less, the action of suppressing the stickiness of glycerin is lost.
【0014】環状または鎖状シリコーンおよび/または
IOBが0.22〜0.85の多価アルコール脂肪酸エ
ステルの合計配合量は0.1〜5.0重量%が好まし
く、この範囲内において最も安定性や使用性が良い。さ
らに、湿潤剤と環状または鎖状シリコーンおよび/また
は多価アルコール脂肪酸エステルとの配合比率は、湿潤
剤1に対して環状または鎖状シリコーンおよび/または
多価アルコール脂肪酸エステル0.5〜2.0(重量
比)が適当であり、この範囲内において最も使用性(べ
たつきの点)が良い。The total amount of polyhydric alcohol fatty acid ester having cyclic or chain silicone and / or IOB of 0.22 to 0.85 is preferably 0.1 to 5.0% by weight, and the most stable amount is within this range. And good usability. Further, the compounding ratio of the wetting agent and the cyclic or chain silicone and / or polyhydric alcohol fatty acid ester is such that the wetting agent 1 is 0.5 to 2.0 of the cyclic or chain silicone and / or polyhydric alcohol fatty acid ester. The (weight ratio) is suitable, and the most usability (point of stickiness) is best within this range.
【0015】本発明の消毒用組成物に含有させることの
できる他の配合物としては、例えばグリチルリチン酸ま
たはその誘導体、ビタミンE,ビタミンEアセテート,
ビタミンB6等の薬剤、キサンタンガム,デキストリ
ン,ヒドロキシエチルセルロース,ヒドロキシメチルセ
ルロース,メチルセルロース,カラギーナン,カルボキ
シメチルセルロース等の水溶性高分子等が挙げられる。Other formulations which can be contained in the disinfecting composition of the present invention include, for example, glycyrrhizic acid or its derivative, vitamin E, vitamin E acetate,
Examples thereof include agents such as vitamin B 6 and water-soluble polymers such as xanthan gum, dextrin, hydroxyethyl cellulose, hydroxymethyl cellulose, methyl cellulose, carrageenan and carboxymethyl cellulose.
【0016】[0016]
【実施例】以下に、本発明の実施例を詳細に説明する
が、本発明はこれにより限定されるものではない。実施
例中の%は特に断らない限り重量%である。 実施例1〜5、比較例1〜3 塩化ベンザルコニウム0.2%およびCAE0.02%
の消毒用エタノール溶液に均一に可溶する湿潤剤、多価
アルコール脂肪酸エステルおよび環状または鎖状シリコ
ーンとして代表的な成分に、グリセリン、トリグリセリ
ド(トリグリセリルトリ2−エチルヘキサノエート)、
環状シリコーン(デカメチルサイクロテトラシロキサ
ン)および鎖状シリコーン(メチルポリシロキサン、2c
s、n=3)を選択し、各成分の濃度を変化させた組み合
わせにおける手荒れ防止効果、使用中のぬめり感、乾燥
後のべたつきおよび乾燥後のしっとり感を20名の使用
試験にて評価した。評価は次の評価点に基づき、20名
の平均値をとることで行った。EXAMPLES Examples of the present invention will be described in detail below, but the present invention is not limited thereto. Unless otherwise specified,% in the examples is% by weight. Examples 1-5, Comparative Examples 1-3 benzalkonium chloride 0.2% and CAE 0.02%
As a representative component as a wetting agent, a polyhydric alcohol fatty acid ester and a cyclic or chain silicone, which is uniformly soluble in an ethanol solution for disinfection, glycerin, triglyceride (triglyceryl tri-2-ethylhexanoate),
Cyclic silicone (decamethylcyclotetrasiloxane) and chain silicone (methylpolysiloxane, 2c
s, n = 3) was selected, and the effect of preventing rough hands, the slimy feeling during use, the stickiness after drying and the moist feeling after drying were evaluated in a use test of 20 people in a combination in which the concentration of each component was changed. . The evaluation was performed by taking the average value of 20 people based on the following evaluation points.
【0017】評価点 3:非常に良い 2:良い 1:普通 0:悪い 各組成物の配合割合および評価結果を表1および表2に
示す。 Evaluation point 3: Very good 2: Good 1: Normal 0: Poor Table 1 and Table 2 show the compounding ratio of each composition and the evaluation results.
【0018】[0018]
【表1】 ──────────────────────────────── 比較例 実施例 配合成分 ───────────────── 1 2 3 1 2 ──────────────────────────────── エタノール 75.0 75.0 75.0 75.0 75.0 グルコン酸クロルヘキシジン − − − − − 塩化ベンザルコニウム 0.2 0.2 0.2 0.2 0.2 CAE 0.02 0.02 0.02 0.02 0.02 グリセリン − − 1.0 1.0 1.0 鎖状シリコーン − − − − − 環状シリコーン − − − − 0.2 トリグリセリド − 0.5 − 0.5 0.3 乳酸 − − − − − 精製水 24.78 24.28 23.78 23.28 23.28 ──────────────────────────────── 使用中のぬめり感 1.5 1.2 1.6 1.1 1.7 乾燥後のべたつき 1.9 1.7 0.8 1.6 1.9 乾燥後のしっとり感 0.7 1.0 1.0 1.8 2.3 ──────────────────────────────── 手荒れ防止効果 0.7 1.6 1.4 2.4 2.4 ────────────────────────────────[Table 1] ──────────────────────────────── Comparative Example Examples Ingredients ──────── ───────── 1 2 3 1 2 ──────────────────────────────── Ethanol 75.0 75.0 75.0 75.0 75.0 Chlorhexidine gluconate − − − − − Benzalkonium chloride 0.2 0.2 0.2 0.2 0.2 CAE 0.02 0.02 0.02 0.02 0.02 Glycerin − − 1.0 1.0 1.0 Chain silicone − − − − − Cyclic silicone − − − − 0.2 Triglyceride − 0.5 − 0.5 0.3 Lactic acid − − − − − Purified water 24.78 24.28 23.78 23.28 23.28 ──────────────────────────────── In use Sliminess 1.5 1.2 1.6 1.1 1.7 Stickiness after drying 1.9 1.7 0.8 1.6 1.9 Moisture after drying 0.7 1.0 1.0 1.8 2.3 ───────────── ─────────────────── Hand roughening prevention effect 0.7 1.6 1.4 2.4 2.4 ──────────────────────── ─────────
【0019】[0019]
【表2】 ──────────────────────────────── 実施例 配合成分 ────────────────── 3 4 5 6 7 ──────────────────────────────── エタノール 75.0 75.0 75.0 75.0 75.0 グルコン酸クロルヘキシジン − − − − 0.2 塩化ベンザルコニウム 0.2 0.2 0.2 0.2 − CAE 0.02 0.02 0.02 0.02 0.02 グリセリン 2.0 1.0 2.0 1.0 1.0 鎖状シリコーン − − − − 0.2 環状シリコーン 0.2 0.5 2.0 0.2 − トリグリセリド 0.3 0.3 3.0 − 0.3 乳酸 − − − − 0.05 精製水 22.28 22.98 17.78 23.58 23.23 ──────────────────────────────── 使用中のぬめり感 1.7 1.2 0.6 1.7 1.7 乾燥後のべたつき 1.4 1.8 0.7 0.8 1.9 乾燥後のしっとり感 2.4 2.0 2.0 1.7 2.3 ──────────────────────────────── 手荒れ防止効果 2.5 2.5 2.7 2.2 2.5 ────────────────────────────────[Table 2] ──────────────────────────────── Example Ingredients ─────────── ──────── 3 4 5 6 7 ──────────────────────────────── Ethanol 75.0 75.0 75.0 75.0 75.0 Chlorhexidine gluconate − − − − 0.2 Benzalkonium chloride 0.2 0.2 0.2 0.2 − CAE 0.02 0.02 0.02 0.02 0.02 Glycerin 2.0 1.0 2.0 1.0 1.0 Chain silicone − − − − 0.2 Cyclic silicone 0.2 0.5 2.0 0.2 − Triglyceride 0.3 0.3 3.0 − 0.3 Lactic acid − − − − 0.05 Purified water 22.28 22.98 17.78 23.58 23.23 ──────────────────────────────── Feeling 1.7 1.2 0.6 1.7 1.7 Stickiness after drying 1.4 1.8 0.7 0.8 1.9 Moisture after drying 2.4 2.0 2.0 1.7 2.3 ─────────────── ───────────────── Hand roughening prevention effect 2.5 2.5 2.7 2.2 2.5 ───────────────────────── ───────
【0020】次に、実施例2の組成物、および従来市販
されているものに近い組成物である比較例1と比較例2
の組成物を用いて手指を消毒し、乾燥させた時における
皮膚のコンダクタンス(μS)の経時変化(分)を測定
した(25℃,50%湿度下で前腕25cm2に試料1
00mlを塗布し、スキコン200(株式会社日本IB
S社製)で各試料のコンダクタンスを測定した。)。そ
の結果を図1に示す。皮膚のコンダクタンスは水分保有
量に相関するものである。したがって、本発明の消毒用
組成物は、皮膚上の水分保有量が大きく、また適用後も
長くその水分を保持するものであることがわかった。Next, the composition of Example 2 and Comparative Examples 1 and 2 which are compositions close to those conventionally commercially available
The time course change (minute) of the conductance (μS) of the skin when the finger was disinfected with the composition of Example 1 and dried (Sample 1 on the forearm 25 cm 2 at 25 ° C. and 50% humidity) was measured.
00 ml was applied and Sukicon 200 (Japan IB Co., Ltd.
S) was used to measure the conductance of each sample. ). The result is shown in FIG. Skin conductance correlates with water retention. Therefore, it was found that the disinfecting composition of the present invention has a large water content on the skin and retains the water for a long time after application.
【0021】実施例8 グルコン酸クロルヘキシジン0.25%の消毒用エタノ
ール溶液に均一に可溶する湿潤剤、多価アルコール脂肪
酸エステルおよび環状または鎖状シリコーンの代表的な
成分に、ソルビトール1.0w/v%、トリグリセリド
(トリグリセリルトリ2−エチルヘキサノエート)0.
3w/v%、環状シリコーン(デカメチルサイクロテト
ラシロキサン)0.2w/v%、さらに殺菌剤としてC
AE0.02w/v%を配合したものを調製し、殺菌効
果を皮膚上で確認した。殺菌効果の確認は次のようにし
て行った。EXAMPLE 8 Sorbitol was added as a typical component of a wetting agent, a polyhydric alcohol fatty acid ester and a cyclic or chain silicone, which was uniformly soluble in a disinfecting ethanol solution containing chlorhexidine gluconate 0.25%, and sorbitol at 1.0 w / v%, triglyceride (triglyceryl tri-2-ethylhexanoate) 0.
3w / v%, cyclic silicone (decamethylcyclotetrasiloxane) 0.2w / v%, and C as a bactericide
A mixture containing AE 0.02 w / v% was prepared, and the bactericidal effect was confirmed on the skin. The bactericidal effect was confirmed as follows.
【0022】黄色ブドウ球菌(Staphylococcus aureus
FDA 209P)を液体ブイヨン培地で37℃,20時間培養
したものを滅菌生理食塩液で2000倍に段階希釈す
る。この液0.1ml(約105cfuの菌を含む。)
を皮膚上に密着させた直径3cmのガラスカップ(筒
状)に注ぎ、滅菌ガラス棒で皮膚表面に塗り付け自然乾
燥する。乾燥後、あらかじめ調製した消毒用組成物を2
mlガラスカップ内に注ぎ滅菌ガラス棒で皮膚表面に十
分に接触させ、1分経過後、この消毒用組成物の0.1
mlをピペットでとり100mlのSCDLP培地に加
えて、37℃,48時間培養したものをフォーゲルジョ
ンソン寒天培地に塗抹し、黄色ブドウ球菌の存在の有無
を確認したところ、白色ブドウ球菌と無胞子桿菌の存在
は確認されたが、あらかじめ接種した黄色ブドウ球菌は
確認されなかったので殺菌されたことが確認出来た。菌
の回収に用いたSCDLP培地はレシチンとポリソルベ
ート80が配合されており、グルコン酸クロルヘキシジ
ンの活性を低下させると共に、100mlで希釈し、発
育阻止が起こらないように工夫した。Staphylococcus aureus
FDA 209P) is cultured in a liquid broth medium at 37 ° C. for 20 hours, and serially diluted 2000 times with sterile physiological saline. 0.1 ml of this liquid (containing about 10 5 cfu of bacteria)
Is poured into a glass cup (cylindrical shape) having a diameter of 3 cm which is in close contact with the skin, and it is applied to the skin surface with a sterilized glass rod and naturally dried. After drying, add the disinfecting composition prepared in advance to 2
Pour it into a ml glass cup and bring it into sufficient contact with the surface of the skin with a sterilized glass rod, and after 1 minute, add 0.1% of this disinfectant composition.
ml was pipetted and added to 100 ml of SCDLP medium, which was cultured at 37 ° C for 48 hours and smeared on Vogel Johnson agar medium, and the presence or absence of Staphylococcus aureus was confirmed. Although the presence was confirmed, the pre-inoculated Staphylococcus aureus was not confirmed, so it was confirmed that the bacteria were killed. The SCDLP medium used for the recovery of the bacteria contained lecithin and polysorbate 80, and it was devised so that the activity of chlorhexidine gluconate was reduced and diluted with 100 ml so that the growth inhibition would not occur.
【0023】実施例9 塩化ベンザルコニウム0.1%の消毒用エタノール溶液
に均一に可溶する湿潤剤、多価アルコール脂肪酸エステ
ルおよび環状または鎖状シリコーンの代表的な成分とし
て、グリセリン、トリグリセリド(トリグリセリルトリ
2−エチルヘキサノエート)および環状シリコーン(デ
カメチルサイクロテトラシロキサン)を選択し、各成分
の濃度をそれぞれグリセリン1.0w/v%、トリグリ
セリド0.3w/v%、環状シリコーン0.2w/v%
とした組み合わせにおけるべたつき防止効果、殺菌効果
を手指上で確認した。Example 9 Glycerin, triglyceride (as a typical component of a wetting agent, a polyhydric alcohol fatty acid ester and a cyclic or chain silicone, which is uniformly soluble in a disinfecting ethanol solution containing 0.1% benzalkonium chloride, Triglyceryl tri-2-ethylhexanoate) and cyclic silicone (decamethylcyclotetrasiloxane) are selected, and the concentration of each component is 1.0 w / v% glycerin, 0.3 w / v% triglyceride, and 0. 2 w / v%
The anti-stickiness effect and the sterilization effect in the above combination were confirmed on the fingers.
【0024】黄色ブドウ球菌(Staphylococcus aureus
FDA 209P)を液体ブイヨン培地で37℃,20時間培養
したものを滅菌生理食塩液で200倍に段階希釈する。
同様に緑膿菌(Pseudomonas aeruginosa)も培養、希釈
する。この希釈液のそれぞれ1ml(約106/mlの
菌を含む。)を手指に取り、まんべんなく擦り付け自然
乾燥する。乾燥後、あらかじめ調製した消毒用組成物を
2ml手指に取りまんべんなく擦り付ける。乾燥後、滅
菌ゴム手袋を手にはめこの中に37℃に保ったLP希釈
液(ダイゴ製)を50ml注ぎ、LP希釈液が漏れない
ように手首をゴムで縛ったのち1分間手袋を揉み、汚染
させた菌を回収した。菌の確認はSCDLP培地とLP
希釈液を用いて行った。ブランクテストとして消毒用組
成物のかわりに50mlの滅菌生理食塩液を用いて行っ
た。消毒用組成物を2ml手指に取り、まんべんなく擦
り付けた後のべたつきも評価した。各々5名で行ったと
きの各パネルごとの結果を表3に示す。なお表中の消毒
後の菌数における5未満(<5)は、菌数測定で検出さ
れなかったことを表す。Staphylococcus aureus
FDA 209P) was cultured in a liquid broth medium at 37 ° C. for 20 hours, and serially diluted 200 times with sterile physiological saline.
Similarly, Pseudomonas aeruginosa is cultured and diluted. 1 ml (each containing about 10 6 / ml of bacteria) of this diluted solution is picked up by fingers, rubbed evenly, and naturally dried. After drying, 2 ml of the disinfecting composition prepared in advance is rubbed evenly on the fingers. After drying, put a sterile rubber glove on your hand and pour 50 ml of LP diluted solution (made by Daigo) kept at 37 ° C into it. Knead the glove for 1 minute after binding the wrist with rubber so that the LP diluted solution does not leak. The contaminated bacteria were collected. Confirmation of bacteria is SCDLP medium and LP
It carried out using the diluent. As a blank test, 50 ml of sterile physiological saline solution was used instead of the disinfecting composition. 2 ml of the disinfecting composition was picked up by fingers, and the stickiness after evenly rubbing was also evaluated. Table 3 shows the results for each panel when performed by 5 persons. In addition, less than 5 (<5) in the number of bacteria after disinfection in the table indicates that the number was not detected by measuring the number of bacteria.
【0025】[0025]
【表3】 [Table 3]
【0026】実施例10 グルコン酸クロルヘキシジン0.2%の消毒用エタノー
ル溶液に均一に可溶する湿潤剤、多価アルコール脂肪酸
エステルおよび環状または鎖状シリコーンの代表的な成
分として、グリセリン1.5w/v%、トリグリセリド
(トリグリセリルトリ2−エチルヘキサノエート)0.
35w/v%、および環状シリコーン(デカメチルサイ
クロテトラシロキサン)0.3w/v%を調製し、連続
使用した時の手荒れ防止効果を皮膚上で確認した。調製
した消毒用組成物を2ml手指に取りまんべんなく擦り
付け乾燥させる。10分経過毎に同様の操作を12回繰
り返した。これを10人が5日間連続して行い手荒れ状
態を自己評価した。その時の各パネルごとの結果を表4
に示す。なお、評価方法は実施例1と同様である。Example 10 Glycerin 1.5 w / as a typical component of a wetting agent, polyhydric alcohol fatty acid ester and cyclic or chain silicone, which is uniformly soluble in a disinfecting ethanol solution containing 0.2% of chlorhexidine gluconate. v%, triglyceride (triglyceryl tri-2-ethylhexanoate) 0.
35 w / v% and 0.3 w / v% of cyclic silicone (decamethylcyclotetrasiloxane) were prepared, and the effect of preventing rough hands when continuously used was confirmed on the skin. 2 ml of the prepared composition for disinfection is rubbed evenly on the fingers and dried. The same operation was repeated 12 times every 10 minutes. This was carried out by 10 people for 5 consecutive days, and the rough condition of the hand was self-evaluated. Table 4 shows the results for each panel at that time.
Shown in. The evaluation method is the same as in Example 1.
【0027】[0027]
【表4】 [Table 4]
【0028】比較例4(本発明の環状または鎖状シリコ
ーン以外のシリコーンを用いた例)次の配合処方で消毒
用組成物を調製した。 エタノール 75.0 重量% 塩化ベンザルコニウム 0.2 CAE 0.02 1,3−ブチレングリコール 1.0 メチルフェニルポリシロキサン 0.2 イソプロピルミリステート(IPM) 0.3 精製水 23.28 得られたものは、使用性的にはシリコーンが揮発性でな
いためにシリコーンとIPMをあわせたものの使用感が
大きくでてしまい、手に被膜感が残り、すべすべしすぎ
るものであった。Comparative Example 4 (Example using silicone other than cyclic or chain silicone of the present invention) A disinfecting composition was prepared by the following formulation. Ethanol 75.0 wt% Benzalkonium chloride 0.2 CAE 0.02 1,3-butylene glycol 1.0 Methylphenyl polysiloxane 0.2 Isopropyl myristate (IPM) 0.3 Purified water 23.28 Obtained In terms of usability, since silicone was not volatile in terms of usability, the usability of the silicone and IPM combined was great, and the film had a filmy feel on the hands, and was too smooth.
【0029】[0029]
【発明の効果】以上説明したように、本発明の消毒用組
成物は、十分な殺菌力を有し、かつ手荒れやべたつきも
ないので、使用頻度の高い医療従事者や看護婦が安心し
て使用できるものである。As described above, since the disinfecting composition of the present invention has sufficient bactericidal power and is free from rough hands and stickiness, it can be safely used by medical staff and nurses who frequently use it. It is possible.
【図1】本発明による消毒用組成物を手に適用した時の
コンダクタンスの経時変化を、従来例による消毒用組成
物の場合と比較して示す図である。FIG. 1 is a diagram showing changes in conductance with time when a disinfecting composition according to the present invention is applied to a hand, as compared with a case of a disinfecting composition according to a conventional example.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 47/44 Z ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Office reference number FI technical display area A61K 47/44 Z
Claims (7)
と、湿潤剤とを含有する消毒用組成物であって、次式: 【化1】[(CH3)2SiO]n または HO−
[(CH3)2SiO]n−H(式中、nは2〜6の整数
を示す。)で表される環状または鎖状シリコーンおよび
/またはIOBが0.22〜0.85の多価アルコール
脂肪酸エステル(但し、脂肪酸は直鎖又は分岐鎖のいず
れでもよい。)がさらに配合されてなることを特徴とす
る消毒用組成物。1. A disinfecting composition containing a lower alcohol, a cationic bactericide, and a wetting agent, which has the following formula: ## STR1 ## [(CH 3 ) 2 SiO] n or HO--
[(CH 3) 2 SiO] n -H ( wherein, n represents an integer of 2-6.) Cyclic or chain silicone and / or IOB represented by the polyvalent 0.22 to 0.85 A disinfecting composition, further comprising an alcohol fatty acid ester (however, the fatty acid may be linear or branched).
リセリン、ジグリセリン、プロピレングリコール、ブチ
レングリコール、エリスリトール、ジプロピレングリコ
ールおよびソルビトールよりなる群から選択される1種
または2種以上である請求項1記載の消毒用組成物。2. The wetting agent is one or more selected from the group consisting of polyethylene glycol, glycerin, diglycerin, propylene glycol, butylene glycol, erythritol, dipropylene glycol and sorbitol. Disinfecting composition.
0.1〜2.0重量%である請求項1記載の消毒用組成
物。3. The disinfecting composition according to claim 1, wherein the compounding amount of the cyclic or chain silicone is 0.1 to 2.0% by weight.
コール脂肪酸エステルがトリグリセリドの1種または2
種以上である請求項1記載の消毒用組成物。4. A polyhydric alcohol fatty acid ester having an IOB of 0.22 to 0.85 is one of triglycerides or two.
The disinfecting composition according to claim 1, which is one or more kinds.
コール脂肪酸エステルの配合量が0.2〜5.0重量%
である請求項1〜4のいずれかに記載の消毒用組成物。5. A compounding amount of a polyhydric alcohol fatty acid ester having an IOB of 0.22 to 0.85 is 0.2 to 5.0% by weight.
The disinfecting composition according to any one of claims 1 to 4.
はIOBが0.22〜0.85の多価アルコール脂肪酸
エステルの合計配合量が0.1〜5.0重量%である請
求項1〜5のいずれかに記載の消毒用組成物。6. The total amount of polyhydric alcohol fatty acid ester having cyclic or chain silicone and / or IOB of 0.22 to 0.85 is 0.1 to 5.0% by weight. The disinfecting composition according to any one.
び/または多価アルコール脂肪酸エステルとの配合比率
が、湿潤剤1に対して環状または鎖状シリコーンおよび
/または多価アルコール脂肪酸エステル0.5〜2.0
(重量比)である請求項1〜6のいずれかに記載の消毒
用組成物。7. The compounding ratio of the wetting agent to the cyclic or chain silicone and / or polyhydric alcohol fatty acid ester is 0.5 to 1 of the cyclic or chain silicone and / or polyhydric alcohol fatty acid ester to the wetting agent. 2.0
It is (weight ratio), The disinfecting composition in any one of Claims 1-6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24874794A JP3996215B2 (en) | 1993-09-21 | 1994-09-16 | Disinfecting composition |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25784493 | 1993-09-21 | ||
| JP5-257844 | 1993-09-21 | ||
| JP24874794A JP3996215B2 (en) | 1993-09-21 | 1994-09-16 | Disinfecting composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07165571A true JPH07165571A (en) | 1995-06-27 |
| JP3996215B2 JP3996215B2 (en) | 2007-10-24 |
Family
ID=26538927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24874794A Expired - Fee Related JP3996215B2 (en) | 1993-09-21 | 1994-09-16 | Disinfecting composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3996215B2 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000273004A (en) * | 1999-03-19 | 2000-10-03 | Nicca Chemical Co Ltd | Germicidal disinfectant composition |
| JP2005068095A (en) * | 2003-08-26 | 2005-03-17 | Mandom Corp | Antiseptic disinfectant and cosmetics, pharmaceuticals and foods containing the antiseptic disinfectant |
| WO2007063828A1 (en) * | 2005-11-29 | 2007-06-07 | Ttm Co., Ltd. | Body fluid sampler and method therefor |
| JP2010508243A (en) * | 2006-09-19 | 2010-03-18 | プロフェッショナル アーティスツ インターナショナル インク. | Bactericides and disinfectants for cosmetics and cosmetic tools |
| JP2011219410A (en) * | 2010-04-08 | 2011-11-04 | Kao Corp | Hand disinfectant composition |
| JP2013538782A (en) * | 2010-03-23 | 2013-10-17 | ゴジョ・インダストリーズ・インコーポレイテッド | Antibacterial composition |
| JP2014145141A (en) * | 2013-01-30 | 2014-08-14 | Nippon Medical School | Adhesiveness reduction composition for glove |
| KR20160063450A (en) * | 2014-11-26 | 2016-06-07 | 건양대학교산학협력단 | Alcoholic disinfectant composition comprsing a pain-relief component, and alcohol swab comprsing the same |
| JP2017132711A (en) * | 2016-01-27 | 2017-08-03 | 株式会社大阪製薬 | Disinfecting emulsified composition |
| WO2022004843A1 (en) * | 2020-07-03 | 2022-01-06 | ロート製薬株式会社 | Composition for external use |
-
1994
- 1994-09-16 JP JP24874794A patent/JP3996215B2/en not_active Expired - Fee Related
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000273004A (en) * | 1999-03-19 | 2000-10-03 | Nicca Chemical Co Ltd | Germicidal disinfectant composition |
| JP2005068095A (en) * | 2003-08-26 | 2005-03-17 | Mandom Corp | Antiseptic disinfectant and cosmetics, pharmaceuticals and foods containing the antiseptic disinfectant |
| WO2007063828A1 (en) * | 2005-11-29 | 2007-06-07 | Ttm Co., Ltd. | Body fluid sampler and method therefor |
| JP2010508243A (en) * | 2006-09-19 | 2010-03-18 | プロフェッショナル アーティスツ インターナショナル インク. | Bactericides and disinfectants for cosmetics and cosmetic tools |
| JP2013538782A (en) * | 2010-03-23 | 2013-10-17 | ゴジョ・インダストリーズ・インコーポレイテッド | Antibacterial composition |
| JP2011219410A (en) * | 2010-04-08 | 2011-11-04 | Kao Corp | Hand disinfectant composition |
| JP2014145141A (en) * | 2013-01-30 | 2014-08-14 | Nippon Medical School | Adhesiveness reduction composition for glove |
| KR20160063450A (en) * | 2014-11-26 | 2016-06-07 | 건양대학교산학협력단 | Alcoholic disinfectant composition comprsing a pain-relief component, and alcohol swab comprsing the same |
| JP2017132711A (en) * | 2016-01-27 | 2017-08-03 | 株式会社大阪製薬 | Disinfecting emulsified composition |
| WO2022004843A1 (en) * | 2020-07-03 | 2022-01-06 | ロート製薬株式会社 | Composition for external use |
| JPWO2022004843A1 (en) * | 2020-07-03 | 2022-01-06 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3996215B2 (en) | 2007-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100344568B1 (en) | Disinfection Composition | |
| KR100437566B1 (en) | Disinfectant composition comprising alcohol, chlorhexidine and an organic acid | |
| US20100029780A1 (en) | Topical composition | |
| JP5026789B2 (en) | Antibacterial compositions and methods | |
| US8193244B1 (en) | Antimicrobial agents | |
| AU2013370926B2 (en) | Improved antimicrobial compositions | |
| JP2008537732A (en) | Antimicrobial composition comprising an ester of hydroxycarboxylic acid | |
| JP6803382B2 (en) | Antibacterial composition for surgical use | |
| KR20070101229A (en) | Antiseptic composition and method of using the same | |
| JP3996215B2 (en) | Disinfecting composition | |
| JP5565902B2 (en) | Hand sanitizer composition | |
| CN102149392B (en) | The gentle non-stimulated skin antiseptic without alcohol | |
| JPH10130173A (en) | Quick-drying disinfectant | |
| JPH10324624A (en) | Disinfectant composition | |
| JPH072615A (en) | Cloth impregnated with antimicrobial disinfectant | |
| WO2004105492A1 (en) | Aqueous compositions for disinfection and/or sterilization | |
| AU2006235798B2 (en) | Topical composition | |
| KR20230006463A (en) | Improved Liquid Compositions for Cleaning, Disinfection and/or Sterilization | |
| JPS6357502A (en) | Antiseptic composition for finger | |
| KR101139517B1 (en) | Hand wash composition | |
| JPH11199476A (en) | Composition for disinfection and/or sterilization | |
| KR20040098400A (en) | Healthcare hand,skinwashing compositions | |
| CN118252760A (en) | Sterilizing wet tissue and preparation method thereof | |
| JPH06256104A (en) | Antibacterial action-sustaining disinfectant | |
| BR112020015681A2 (en) | DISINFECTANT COMPOSITION, METHOD FOR DISINFECTING A TOPICAL SURFACE OF A HUMAN BODY AND USE OF A COMPOSITION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040518 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040716 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040922 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050817 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070802 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100810 Year of fee payment: 3 |
|
| R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100810 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100810 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110810 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110810 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120810 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130810 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |